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Abstract 23 
 24 
Background  25 
Associations between antimicrobial exposure in the community and community-associated 26 
Clostridioides difficile infection (CA-CDI) are well documented but associations with 27 
healthcare-associated CDI (HA-CDI) are less clear. This study estimates the association 28 
between antimicrobial prescribing in the community and HA-CDI. 29 
Methods 30 
A matched case-control study was conducted by linking three national patient level datasets 31 
covering CDI cases, community prescriptions and hospitalisations. All validated cases of HA-32 
CDI (August 2010 - July 2013) were extracted and up to three hospital-based controls were 33 
matched to each case on the basis of gender, age, hospital and date of admission. Conditional 34 
logistic regression was applied to estimate the association between antimicrobial prescribing 35 
in the community and HA-CDI. We conducted sensitivity analysis to consider the impact of 36 
unmeasured hospital antimicrobial prescribing. 37 
Results 38 
930 unique cases of HA-CDI with onset in hospital and no hospital discharge in the 12 weeks 39 
prior to index admission were linked with 1810 matched controls. Individuals with prior 40 
prescription of any antimicrobial in the community had an odds ratio (OR) = 1.40 (95% CI 1.13-41 
1.73) for HA-CDI compared to those without. Individuals exposed to high risk antimicrobials 42 
(cephalosporins, clindamycin, co-amoxiclav, or fluoroquinolones) had an OR=1.83 (95% CI: 43 
1.31-2.56). After accounting for the likely impact of unmeasured hospital prescribing, the 44 
community exposure, particular to high risk antimicrobials, was still associated with elevated 45 
HA-CDI risk. 46 
Conclusions 47 
Community antimicrobial exposure is an independent risk factor for HA-CDI and should be 48 
considered as part of the risk assessment of patients developing diarrhoea in hospital.   49 
Introduction 50 
 51 
Clostridioides difficile infection (CDI) is a global challenge1,2 and a major public health problem 52 
in both healthcare and community settings. In Scotland, the annual incidence of healthcare-53 
associated CDI (HA-CDI) in 2016 was 15.4 per 100 000 total bed days compared to 7.5 per 100 54 
000 population for community-associated CDI (CA-CDI)3. Although a reduction in HA-CDI in 55 
Scotland has been observed over time, 58% of all cases were HA-CDI in 2016. 56 
Antimicrobial exposure is a significant risk factor for CDI that is potentially modifiable. 57 
Associations between community antimicrobial exposure and CA-CDI are clearly 58 
demonstrated4-7, but any residual impact on the risk of HA-CDI is challenging to differentiate 59 
from the impact of antimicrobial exposure in the healthcare setting. A recent systematic 60 
review, found that overall exposure to antimicrobials was associated with a 60% (95% CI 30%-61 
90%) increased risk of HA-CDI however the included studies either only looked at hospital 62 
prescribing or did not differentiate between community and hospital prescribing8. No studies 63 
examined the residual effect of community prescribing on the risk of HA-CDI, and there were 64 
limited large studies to enable accurate quantification of the risk of antimicrobial prescribing 65 
on HA-CDI8.  66 
This study included all HA-CDI cases in Scotland (population of ~5.3 million) enabled through 67 
our national Infection Intelligence Platform (IIP) which synergizes the wealth of infection-68 
related health data to provide timely and efficient analysis of our antimicrobial stewardship 69 
programs10. 70 
The aims of this study are to estimate the association between antimicrobial prescribing in 71 
the community and the development of HA-CDI considering exposure to, (i) any antimicrobial 72 
and (ii) specific broad spectrum antimicrobials, whilst accounting for the unmeasured 73 
confounder of hospital antimicrobial prescribing. The effect of cumulative antimicrobial 74 
exposure on the risk of HA-CDI and the temporal relationship between timing of antimicrobial 75 
exposure and risk of HA-CDI are also examined. 76 
  77 
Population and methods 78 
 79 
Data Linkage & Case-Control Assignment 80 
 81 
A matched case control study was conducted by linking three national patient level datasets: 82 
ECOSS (Electronic Communication of Surveillance in Scotland – positive microbiology 83 
laboratory specimens for key infections); SMR01 (Scottish Morbidity Record– the General / 84 
Acute and Inpatient Day Case dataset recording hospital discharges); PIS (Prescribing 85 
Information System – prescriptions dispensed in the community)10. The completeness for 86 
SMR01 extract is around 99%11 and for PIS extract is over 87%12. Due to mandatory 87 
surveillance for CDI in Scotland13, our data should capture all CDI cases. The datasets were 88 
linked using the unique patient identifier, the community health index (CHI), used across all 89 
health service contacts in Scotland.  90 
 91 
All validated CDI cases with a date of testing between August 2010 (to allow 1 year of look 92 
back of community prescriptions on PIS) and July 2013 (most recent validated CDI case data 93 
available at time of data extraction) were extracted from ECOSS.  All diarrhoeal samples are 94 
tested using a 2-step diagnostic algorithm: first step, - screen for the presence of C. difficile 95 
glutamate dehydrogenase antigen; second step, test for the presence of toxin A/B in enzyme 96 
immunoassay (only samples positive in both steps are reported as positive). Positive tests 97 
were then validated by the NHS board against local laboratory and patient records to confirm 98 
all clinically symptomatic CDI episodes and entered into ECOSS.   99 
 100 
Cases were linked to hospitalisation history from SMR01 for case classification. Cases were 101 
categorised as HA-CDI if the date of positive test was on day three or later of a hospital 102 
admission and/or within four weeks of a previous hospital discharge14. For this study, only 103 
hospital-onset HA-CDI (HO HA-CDI) cases were included, cases with hospital discharge in the 104 
12 weeks prior to index admission were excluded to minimise the impact of unmeasured risk 105 
factors in previous admissions.  For cases with multiple episodes of HA-CDI, one episode was 106 
chosen randomly for inclusion. 107 
 108 
Up to three hospital based controls were matched to cases on the basis of age (within 5 years), 109 
gender, hospital and admission date (within 7 days, and in hospital on the case’s CDI test 110 
date). Controls were excluded if they had hospitalisation in the 12 weeks prior to the current 111 
admission.  112 
 113 
Individual community prescription records from August 2009 onwards and five years of 114 
hospitalisation records prior to the CDI date were linked to cases and controls using CHI. Two 115 
antimicrobial exposure categories in the six months prior to CDI test date were considered; 116 
any antimicrobial (only antibacterials not antiviruals or antifungals; Leprosy and TB are very 117 
different to most other antibacterials and not implicated in CDI so excluded) and, separately, 118 
a higher risk group (clindamycin, cephalosporins, fluoroquinolones and co-amoxiclav – 119 
referred to as “4C” antimicrobials). This group of broad-spectrum antibiotics have been 120 
shown to have a higher risk of contributing to CDI4,6,8,9. Detailed prescribing directions were 121 
not available but strength and volume information allowed calculation of each prescription 122 
and cumulative exposure as WHO defined daily doses (DDDs)15. DDD is the average 123 
maintenance dose per day for a drug used for its main indication in adults15. 124 
 125 
Risk factors considered were: hospital admission (yes/no) in the year prior to CDI;  burden of 126 
co-morbidities derived from prescribing - number of total prescriptions (all drugs) and 127 
number of different prescriptions (based on approved name) dispensed in the year prior to 128 
CDI16 and the Charlson Index - based on International Classification of Diseases 10 (ICD 10) 129 
discharge codes from all hospital admissions in the 5 years prior to CDI17-19; speciality for the 130 
index admission; care home residency (yes/no); Scottish Index of Multiple Deprivation (SIMD) 131 
quintile20 from CHI Registry; length of inpatient stay before infection (days from index 132 
admission until CDI test date – each control used the pseudo CDI test date from the matched 133 
case); proton pump inhibitor (PPI) and H2 antagonist exposure (present/absent) in the six 134 
months prior to CDI. 135 
 136 
 137 
Analysis  138 
The association between community antimicrobial exposure and HA-CDI was assessed using 139 
conditional logistic regression with all other risk factors adjusted for. The residual effect of 140 
community antimicrobial exposure might be stronger in those hospitalised for a shorter 141 
period of time therefore interaction tests were used to investigate if the effect was the same 142 
in those hospitalised for under or over seven days prior to CDI.  143 
 144 
For sensitivity analyses, we modelled how the unknown hospital prescribing of antimicrobials 145 
during the index CDI admission may influence the estimates21. The method specifies the likely 146 
proportion of unknown hospital antimicrobial prescribing in those exposed and unexposed to 147 
antimicrobials in the community along with the estimate of effect size of hospital prescribing 148 
on HA-CDI from the systematic review 8. We assumed three potential values for the increased 149 
odds of HA-CDI associated with hospital antimicrobial prescription, OR=1.6, 1.3 and 1.9 (point 150 
estimate and confidence boundaries) and more extreme scenarios of OR= 4 and 6. One third 151 
of hospital inpatients are on antimicrobials at any time22 and we assumed that those with a 152 
community antimicrobial prescription were more likely to have a hospital antimicrobial 153 
prescription, so we considered imbalances in the proportions with hospital prescribing from 154 
35%/31% to 47%/19% in those with/without community prescribing, respectively. 155 
Uncertainty around the antimicrobial prevalence among hospital inpatients and its impact on 156 
the results was also investigated – we changed the overall prevalence from assumed 33% to 157 
25%, 50% and 75% and reran the analysis. All analysis was conducted using R version 3.2.1.  158 
Results 159 
 160 
In total there were 3727 HA-CDI episodes in the time frame, of which 1235 (33.1%) were 161 
hospital onset and had no hospitalisation in the prior 12 weeks (Figure 1).  Matched controls 162 
(1867) were obtained for 961 cases and after randomly selecting one episode from those with 163 
multiple episodes, 930 cases and 1810 matched controls were identified.  164 
 165 
The study population was 59% female with median age 79 years (Table I). The average days 166 
of current hospitalisation before the matched date of CDI is longer for cases compared to 167 
controls (17 vs. 14 days). The cases were more likely than controls to have at least 1 prior 168 
hospital admission in previous year (44.4% vs. 39.1 %) but less likely to be resident in a care 169 
home (19.1% vs. 23.7%). The adjusted model showed that, there was increased risk of HA-CDI 170 
associated with comorbidity (Charlson score 4+ vs. 0 OR=2.72 95% CI: 1.63-4.53), higher 171 
numbers of drugs dispensed in the previous year (for unit increase OR=1.01 95% CI: 1.01-1.02 172 
for each additional drug), a longer duration of hospitalisation prior to infection (OR=1.11 95% 173 
CI: 1.08-1.15 for each additional day), previous hospital admissions (yes vs. no OR=1.30 95% 174 
CI: 1.04-1.63), no care home residency (yes vs.no OR=0.65 95% CI: 0.50-0.83) (Table I).  175 
 176 
Compared to the controls, a higher proportion of cases received any antimicrobial (42.6% 177 
vs.39.6%) and 4C group (13.0% vs. 9.6%) in the community in the previous 6 months. After 178 
adjusting for all other variables, prior antimicrobial exposure vs. no exposure in the 179 
community was associated with 40% increased odds of HA-CDI (OR 1.41 95% CI: 1.13 -1.75) 180 
(Table 1).  The OR was higher for exposure to 4Cs (OR=1.86 95% CI: 1.33-2.59). 181 
 182 
The effect of community 4C exposure was stronger in those hospitalised for less than one 183 
week prior to CDI diagnosis (Interaction test: p=0.02). For patients hospitalised for less than 184 
one week the OR for community 4C exposure vs. no exposure was 2.43 (95% CI: 0.998, 5.94) 185 
(Table II). 186 
 187 
The scale of the dose response relationship between prior exposure to any antimicrobial in 188 
the community and development of HA-CDI was not found to be particularly large (1-7 DDDs 189 
exposure adjusted OR=1.31 95% CI: 0.95-1.79; 29+ DDDs OR=1.90 95% CI: 1.31-2.74) although 190 
the p value for the linear trend test was significant (p=0.0006).  A similar result was found for 191 
dose response of prior 4C exposure was - compared to no exposure (Table III).  192 
 193 
A slight decreasing trend can be observed in the risk of developing CDI with time since any 194 
antimicrobial exposure, adjusted OR for <=30 days post exposure was 2.17 (95% CI: 1.53 - 195 
3.07) and decreasing to 1.75 (95% CI: 1.27-2.41) for 31-90 days post exposure and 0.97 (95% 196 
CI: 0.74-1.28) for 91 or more days, but the trend was not statistically significant (linear trend 197 
test p=0.5) (Table IV). The effect of 4C exposure was strongest within 90 days with little 198 
difference between the first month and those subsequent (OR <=30 days, 2.24 (95% CI: 1.32 199 
-3.78) and OR 31-90 days, 2.47 (95% CI: 1.42-4.32)). The association did not persist after 90 200 
days post exposure (OR 1.27 95% CI: 0.76-2.12). 201 
 202 
The potential impact of unknown hospital antimicrobial prescribing on the association 203 
between community antimicrobial prescription and HA-CDI was examined, with reasonably 204 
assumed parameters for unknown hospital prescribing (ORs for hospital prescribing to 205 
develop HA-CDI, prevalence of hospital prescribing in those with community exposure (p1) 206 
and without (p0)), Table V. With the increase in odds of HA-CDI associated with hospital 207 
antimicrobial exposure set at OR=1.6 the effect of any community antimicrobial exposure lost 208 
statistical significance at an imbalance in hospital exposure, between p0 and p1, of 19% versus 209 
47% (OR =1.22 95% CI: 0.98-1.52). However community 4C exposure remained significantly 210 
associated with increased odds of HA-CDI at this imbalance (OR =1.61 95% CI: 1.15-2.25). If 211 
the OR for hospital prescribing is increased to 6, the effect of any antimicrobial prescribing in 212 
the community became insignificant at imbalance of p0 = 29% to p1=37% while the effect of 213 
4C became insignificant at a larger imbalance of p0=25% to p1=41%. The results in Table V 214 
assumed that the overall prevalence of hospital prescribing was 33%. The impact of the 215 
variation of this overall prevalence to the results was investigated in Table A1. When the OR 216 
for hospital prescribing is low (OR=1.3) increasing the overall prevalence of hospital 217 
prescribing had little impact (up to 75%) on the measured association between HA-CDI and 218 
community prescribing. With a higher association (OR=6) a difference of difference between 219 
p0 and p1 of 4%, still showed significant associations even with a prevalence of hospital 220 
prescribing at 75%, however if the differential was greater (14%, 28%) then the association 221 
became reduced and the estimated odds became insignificant.   222 
Discussion 223 
 224 
Summary main findings 225 
This study examined the residual effect of antimicrobial prescribing in the community on the 226 
risk of HA-CDI. Prior antimicrobial exposure vs. no exposure in the previous 6 months in 227 
community was associated with 40% increased odds of HA-CDI, rising to 80% after exposure 228 
to a higher risk antimicrobials group. After accounting for unmeasured hospital antimicrobial 229 
exposure, community exposure, particularly to high risk antimicrobials, still appeared to 230 
influence the risk of HA-CDI. 231 
Strengths and limitations 232 
The 2014 review paper8 summarized the results on associations between prior antimicrobial 233 
exposure and the risk of HA-CDI. However, no studies examined community prescribing alone 234 
- three studies measured exposure during admission only whilst 10 studies measured 235 
antimicrobials received prior to and during admission combined. More recent work by 236 
Khanafer et al23 also only explored hospital prescribing. This study examined the independent 237 
risk of community prescribing on developing HA-CDI, not explored previously to our 238 
knowledge.   Additionally, most previous studies examined antimicrobial exposure in the prior 239 
4-6 week while our study included exposure up to 6 months before infection.   240 
Furthermore, our study is also at scale, second largest only to the USA Kaiser study24, the 241 
remaining studies in the review comprising mainly of one hospital site with two studies 242 
covering 9-12 hospital sites (n=317 and n=237).  In contrast, our study covered a national 243 
health system with data from 40 hospitals.  244 
A limitation of our study was the unmeasured confounder of hospital prescribing. To minimise 245 
this impact, we excluded cases with a hospitalisation in the preceding 12 weeks. Sensitivity 246 
analysis, using an approach demonstrated in other clinical studies25-26, was applied.  Our study 247 
showed the impact of community prescribing on HA-CDI reduced when the likely impact of 248 
hospital prescribing8 was accounted for but generally remained significant.  249 
All our HA-CDI cases were defined according to the clinical definition14 however cut-offs in 250 
the definition are in fact relatively arbitrary and there is much more of a continuum between 251 
the community and hospitals in terms of exposures, i.e. antimicrobials, and risk of infection 252 
transmission. Cases are attributed based on symptoms/sampling rather than when/where the 253 
bacteria was initially acquired (because it is common to have a period of asymptomatic 254 
carriage) so it is possible that some cases are misclassified in terms of acquisition source. 255 
A proportion of PPI/H2 antagonist consumption is likely attributable to over the counter use, 256 
which we cannot measure in this study and we are therefore likely to be  underestimating 257 
exposure to PPI/H2 antagonists which could modify the associations found if there is an 258 
imbalance in over the counter use between cases and controls.  259 
Data subsequently recorded since the time of the study (2013-2017), shows a decreasing year 260 
on year trend of 6.8% in the incidence rate of CDI in Scotland and a contemporaneous 261 
decrease of 10.8% in 4C prescribing in the community27, in line with antimicrobial stewardship 262 
policies. Given that our data predate this period, it is possible that changes in prescribing 263 
behaviour may have modified the relationships observed although the ecological pattern of 264 
a decrease in CDI with reductions in community prescribing, is consistent with the 265 
associations found in this study and in our previous work on community associated CDI7.  266 
Future work will seek to use an updated data extract and examine the impact of the change 267 
in prescribing on the associations found.  268 
Comparison with other work 269 
The review paper8 estimated ORs for different classes of antimicrobials (penicillins, 270 
clindamycin, trimethoprim, cephalosporins, carbapenems and fluoroquinolones; combined 271 
prior hospital and community prescribing) for risk of HA-CDI ranging from 1.45 (95% CI: 1.05-272 
2.02) for penicillin to 3.2 for third-generation cephalosporins (95% CI: 1.8-5.71) which was 273 
generally higher than our estimations for community prescribing to any antimicrobial 274 
(OR=1.41 95% CI: 1.13-1.75) and 4C (OR = 1.86 95% CI: 1.33-2.59). The differences are 275 
expected as our study estimated the residual risk from community prescribing whilst the 276 
other studies mainly quantified the risk of mixed hospital and community prescribing. 277 
Another potential contributory factor to the difference may be the variation in definition of 278 
HA-CDI within the review which led to high heterogeneity in the estimated pooled risk 279 
(ranging from >48 hours to >72 hours with one study >5 days and variation in hospitalisation 280 
prior to the index admission). 281 
Cumulative total exposure to any antimicrobial has been demonstrated to increase HA-CDI 282 
risk5,25,29 but community prescribing was not investigated alone in these studies. We found a 283 
lower effect of cumulative community exposure (OR=1.90 95% CI: 1.31-2.74 for >29 DDDs, 6 284 
months prior to CDI) compared to Hensgens et al who reported OR=8.5 95% CI: 4.6-15.9 for 285 
>=14 DDDs any antimicrobial use in both community and hospital in the 3 month prior to CDI, 286 
the difference most likely attributable to hospital prescribing. Further investigation of the 287 
cumulative exposure to the 4C subgroup is required due to small numbers in all studies to 288 
date.  289 
In our study, community exposure to PPI and H2 antagonist was not associated with an 290 
increased risk of HA-CDI – similar to23 where hospital exposure to PPI/H2 was examined with 291 
adjustment of prior antimicrobial use.  However, the impact of PPI/H2 on CDI remains 292 
uncertain with  Aseeri et al30 showing a significant increased CDI risk for inpatients with 293 
combined community and hospital PPI exposure (OR=3.08 95% CI: 1.61-5.91) when the cases 294 
and controls were matched on type, amount and duration of prior antimicrobial exposure.   295 
 296 
Finally, previous studies report care home residents as having higher risk of CDI6-7, due to 297 
increasing age, comorbidity, likelihood for infection transmission and antimicrobial 298 
exposure31. However, care home residents appeared to be at lower risk of HA-CDI in our study 299 
(adjusted OR=0.65 95% CI: 0.50-0.83). This is likely due to the selection of controls, matched 300 
on age, gender and length of admission before CDI diagnosis date, resulting in a relatively high 301 
proportion of care home residents (23.7% vs. 19.1% of cases). 302 
 303 
Conclusions 304 
 305 
It appears that community prescribing has an impact on risk of hospital onset HA-CDI.  306 
Additionally, the study has shown that the impact on risk of HO HA-CDI from antimicrobial 307 
exposure in the community can persist for up to 6 months, not reported before8,23.  308 
 309 
This evidence underpins our national strategy to continue to strive for a reduction in broad 310 
spectrum antibiotics, now evidenced by a decline in CDI rates and 4C prescribing31. Our 311 
findings also raise the awareness of the persistence of community exposure on risk during 312 
hospital stay, noteworthy for the risk assessment and management of patients developing 313 
diarrhoea both in Scotland and globally.   314 
 315 
Our study has used large scale data analytics to identify and quantify risk association 316 
retrospectively. The next phase is to link national data prospectively to inform new clinical 317 
decision tools using individual characteristics to derive personalised risk profiles to shape 318 
therapeutic management plans in the clinical setting.  319 
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Table I:  Demographics, univariate and multivariate odds ratios of prior antimicrobial exposure and potential confounding variables for 455 
Healthcare associated CDI cases (HA-CDI) vs. hospital based controls. 456 
 457 
  Cases (n=930) 
n(%); 
Controls 
(n=1810) n(%); 
Unadjusted Adjusted (Any) Adjusted (4C) 
  median (IQR)a median (IQR)a OR (95% CI) OR (95% CI) OR (95% CI) 
No exposure to antibiotics in the previous 6 months 534 (57.4) 1093 (60.4) 1 1 1 
Exposed to antibiotics in the previous 6 months 396 (42.6) 717 (39.6) 1.22 (1.02, 1.45) 1.41 (1.13, 1.75) - 
Exposed to non-4C in the previous 6 months 275 (29.6) 544 (30.1) 1.11(0.92, 1.36) - 1.86 (1.33, 2.59) 
Exposed to 4C in the previous 6 months 121 (13.0) 173 (9.6) 1.50 (1.15, 1.97) - 1.29 (1.02, 1.63) 
Age 79 (70-86) 80 (72-86) - - - 
Female 536 (57.6) 1086 (60.0) - - - 
SIMD 1: most deprived 237 (25.6) 445 (24.7) 1 1 1 
SIMD 2 223 (24.1) 386 (21.4) 1.07 (0.82, 1.39) 1.06 (0.79, 1.42) 1.05 (0.78, 1.41) 
SIMD 3 159 (17.2) 348 (19.3) 0.82 (0.62, 1.10) 0.81 (0.60, 1.11) 0.81 (0.59, 1.11) 
SIMD 4 156 (16.9) 324 (18.0) 0.86 (0.65, 1.15) 0.94 (0.68, 1.29) 0.94 (0.68, 1.29) 
SIMD 5: least deprived 150 (16.2) 297 (16.5) 0.97 (0.72, 1.31) 1.08 (0.77, 1.52) 1.07 (0.76, 1.51) 
Unknown 5 10 - - - 
Charlson score 0 375 (40.3) 775 (42.8) 1 1 1 
Charlson score 1 156(16.8) 266 (14.7) 1.32 (1.02, 1.72) 1.20 (0.90, 1.61) 1.21 (0.90, 1.62) 
Charlson score 2 110 (11.8) 210 (11.6) 1.15 (0.86, 1.54) 1.18 (0.86, 1.63) 1.16 (0.84, 1.6)0 
Charlson score 3 52 (5.6) 81 (4.5) 1.46 (0.98, 2.17) 1.28 (0.82, 2.01) 1.28 (0.82, 2.01) 
Charlson score 4+ 46 (5.0) 50 (2.8) 2.25 (1.42, 3.55) 2.72 (1.63, 4.53) 2.71 (1.62, 4.52) 
Charlson score Unknownb 191 (20.5) 428 (23.7) 0.93 (0.74, 1.18) 1.06 (0.79, 1.41) 1.05 (0.79, 1.41) 
Admission speciality: general medicine 467 (50.2) 921 (50.9) 1 1 1 
Admission speciality: geriatric medicine 67 (7.2) 123 (6.8) 1.22 (0.84, 1.77) 1.20 (0.79, 1.82) 1.20 (0.79, 1.83) 
Admission speciality: surgery 298 (32.0) 547(30.2) 1.06 (0.87, 1.30) 1.14 (0.90, 1.44) 1.15 (0.91, 1.45) 
Admission speciality: otherc 98 (10.5) 219 (12.1) 0.85 (0.62, 1.15) 0.86 (0.61, 1.2) 0.86 (0.61, 1.21) 
Any hospital admission in previous year, No 517 (55.6) 1103 (60.9) 1 1 1 
Any hospital admission in previous year, Yes 413 (44.4) 707 (39.1) 1.26 (1.06, 1.49) 1.30 (1.04, 1.62) 1.28 (1.03, 1.60) 
Number items dispensed in previous yeard 65.5 (31-114.8) 51 (27.3-86) 1.01 (1.01, 1.01) 1.01 (1.01, 1.02) 1.01 (1.01, 1.02) 
Number different items dispensed in previous yeard 12 (8-18) 12 (8-17) 1.01 (0.9993, 1.02) 0.92 (0.90, 0.94) 0.91 (0.89, 0.93) 
Length of inpatient stay before the date of CDId 17 (8-34) 14 (6-30) 1.11 (1.08, 1.14) 1.11 (1.08, 1.15) 1.12 (1.08, 1.15) 
Care home residence, No 752 (80.9) 1381 (76.3) 1 1 1 
Care home residence, Yes 178 (19.1) 429 (23.7) 0.75 (0.59, 0.94) 0.65 (0.50, 0.83) 0.65 (0.50, 0.84) 
PPI exposure, No 516 (55.5) 1032 (57.0) 1 1 1 
PPI exposure, Yes 414 (44.5) 778 (43.0) 1.09 (0.91, 1.29) 0.94 (0.76, 1.16) 0.95 (0.77, 1.18) 
H2 exposure, No 871 (93.7) 1707 (94.3) 1 1 1 
H2 exposure, Yes 59 (6.3) 103 (5.7) 1.20 (0.85, 1.70) 1.00 (0.67, 1.49) 1.01 (0.68, 1.51) 
aIQR means inter quartile range. bCharlson score is unknown means that the patient has not been admitted to hospital in the 5 years before the current admission date. cother include: Acute medicine, Cardiology, 458 
Infectious disease, Dermatology, Gastroenterology, Renal medicine, Neurology, Respiratory medicine, Rheumatology, Accident and emergency, Ear nose and throat, Ophthalmology, Urology, GP other than 459 
obstetrics. dOdds ratio for continuous variables are for every unit increase. 460 
Table II:  Subset analysis for those hospitalised less than one week - multivariate odds ratios 461 
of prior 4C exposure and potential confounding variables for HA-CDI vs. controls (221 cases 462 
and 559 controls).  463 
 464 
  Adjusted 4C 
  OR (95% CI) 
Exposed to antibiotics in the previous 6 months, No 1 
Exposed to 4C in the previous 6 months 2.43 (0.998, 5.94) 
Exposed to non-4C in the previous 6 months, Yes 1.11 (0.61, 1.99) 
SIMD 1: most deprived 1 
SIMD 2 1.28 (0.64, 2.56) 
SIMD 3 0.97 (0.47, 2.00) 
SIMD 4 1.54 (0.67, 3.52) 
SIMD 5: least deprived 0.97 (0.41, 2.31) 
Charlson score 0 1 
Charlson score 1 1.09 (0.49, 2.45) 
Charlson score 2 0.80 (0.35, 1.08) 
Charlson score 3 1.88 (0.51, 6.89) 
Charlson score 4+ 9.47 (1.89, 47.56) 
Charlson score Unknown 0.47 (0.23, 0.99) 
Admission speciality: general medicine 1 
Admission speciality: geriatric medicine 1.56 (0.45, 5.43) 
Admission speciality: surgery 0.33 (0.14, 0.80) 
Admission speciality: other 0.65 (0.35, 1.21) 
Any hospital admission in previous year, No 1 
Any hospital admission in previous year, Yes 1.21 (0.72, 2.06) 
Number items dispensed in previous year 1.01 (1.01, 1.02) 
Number different items dispensed in previous year 0.92 (0.86, 0.98) 
Length of inpatient stay before the date of CDI 1.73 (1.49, 2.00) 
Care home residence, No 1 
Care home residence, Yes 1.11 (0.57, 2.19) 
PPI exposure, No 1 
PPI exposure, Yes 1.03 (0.62, 1.73) 
H2 exposure, No 1 
H2 exposure, Yes 0.98 (0.41, 2.33) 
465 
Table III:  The effect of cumulative exposure in a six month period on the adjusted odds of 466 
HA-CDI.  467 
 468 
Cumulative 
antimicrobial 
exposure 
Cases (n=930) 
N (%) 
Controls (n=1810) 
N (%) 
Adjusteda 
OR (95% CI) 
Global P value 
no antimicrobials 534 (57.4) 1093 (60.4) 1 0.0006b 
1-7 DDDs 96 (10.3) 213 (11.8) 1.31 (0.95, 1.79)  
8-14 DDDs 100 (10.8) 208 (11.5) 1.40 (1.03, 1.92)  
15-28 DDDs 80 (8.6) 163 (9.0) 1.21 (0.85, 1.72)  
29+ DDDs 120 (12.9) 132 (7.3) 1.90 (1.31, 2.74)  
NAc 0 1 
 
 
Cumulative 4C 
exposure 
 
no antimicrobials 534 (57.4) 1093 (60.4) 1 0.006d 
1-7 DDDs 48 (5.2) 89 (4.9) 1.76 (1.14, 2.73)  
8-14 DDDs 29 (3.1) 41 (2.3) 2.16 (1.19, 3.91)  
15-28 DDDs 21 (2.3) 26 (1.4) 1.94 (0.93, 4.03)  
29+ DDDs 23 (2.5) 16 (0.9) 1.63 (0.69, 3.84)  
Only non-4C 275 (29.6) 545 (30.1) 1.29 (1.02, 1.63)  
aModels are adjusted for SIMD, Charlson score, speciality for the index admission, any hospitalisation in the previous year (y/n), total 469 
number of prescriptions in the previous year, total number of different prescriptions, days since the index admission until CDI, care home 470 
residence,   PPI H2 exposure. bLinear p value (trend test). cTo calculate DDD exposure both quantity and a scaling factor representing the 471 
recommended daily dose are required.  For one observations either or both of these were missing for the antimicrobial exposure variable.  472 
The observation are excluded from the analysis. dglobal p value, not trend test p value (trend test was not possible as “Only non-4C” 473 
making the  levels not ordered).474 
Table IV:  Distribution of temporal antimicrobial exposure and the adjusted odds of HA-CDI.  475 
 476 
Most recent 
exposure in 
previous 6 months 
(any antimicrobial) 
Cases (n=930) 
N (%) 
Controls (n=1810) 
N (%) 
Adjusteda 
OR (95% CI) 
Global P value 
no antimicrobials 534 (57.4) 1093 (60.4) 1 0.5b 
<=30 days 94 (10.1) 120 (6.6) 2.17  (1.53, 3.07)  
31-90 days 126 (13.5) 191 (10.6) 1.75 (1.27, 2.41)  
91+ days 176 (18.9) 406 (22.4) 0.97  (0.74, 1.28)  
Most recent 
exposure in 
previous 6 months 
(4C) 
 
no antimicrobials 534 (57.4) 1093 (60.4) 1 0.003c 
<=30 days 45 (4.8) 51 2.8) 2.24 (1.32, 3.78)  
31-90 days 39 (4.2) 44 (2.4) 2.47 (1.42, 4.32)  
91+ days 37 (4.0) 77 (4.3) 1.27 (0.76, 2.12)  
Only non-4C 275 (29.6) 545 (30.1) 1.29 (1.02, 1.63)  
aModels are adjusted for SIMD, Charlson score, speciality for the index admission, any hospitalisation in the previous year (y/n), total 477 
number of prescriptions in the previous year, total number of different prescriptions, days since the index admission until CDI, care home 478 
residence,   PPI H2 exposure. bLinear p value (trend test). cglobal p value, not trend test p value (trend test was not possible as “Only non-479 
4C” making the levels not ordered). 480 
Table V: Adjusted odds of HA-CDI associated with community prescribing of antimicrobials 481 
(Baseline) and assessment of the potential unmeasured confounder.  482 
 483 
hospital 
prescribing 
ratio: P0/P1b 
Any antimicrobial 
Adjusteda OR of community prescribing (95% CI) 
ORc=1.3 ORc=1.6 ORc=1.9 ORc=4 ORc=6 
33/33 
(baseline) 
1.41 (1.13, 1.75) 1.41 (1.13, 1.75) 1.41 (1.13, 1.75) 1.41 (1.13, 1.75) 1.41 (1.13, 1.75) 
31/35 1.39 (1.12, 1.73) 1.38 (1.11, 1.71) 1.37 (1.10, 1.70) 1.32 (1.07, 1.64) 1.30 (1.05, 1.62) 
29/37 1.38 (1.11, 1.71) 1.35 (1.09, 1.68) 1.33 (1.07, 1.65) 1.25 (1.00, 1.55) 1.21 (0.97, 1.50) 
27/39 1.36 (1.10, 1.69) 1.32 (1.07, 1.64) 1.29 (1.04, 1.61) 1.17 (0.95, 1.46) 1.12 (0.90, 1.39) 
25/41 1.35 (1.08, 1.67) 1.30 (1.05, 1.61) 1.26 (1.01, 1.56) 1.10 (0.89, 1.37) 1.04 (0.84, 1.29) 
23/43 1.33 (1.07, 1.65) 1.27 (1.02, 1.58) 1.22 (0.99, 1.52) 1.04 (0.84, 1.29) 0.96 (0.77, 1.19) 
21/45 1.32 (1.06, 1.64) 1.25 (1.00, 1.55) 1.19 (0.96, 1.48) 0.98 (0.79, 1.21) 0.89 (0.71, 1.10) 
19/47 1.30 (1.05, 1.62) 1.22 (0.98, 1.52) 1.16 (0.93, 1.44) 0.92 (0.74, 1.14) 0.82 (0.66, 1.02) 
 
4C 
Adjusteda OR of community prescribing (95% CI) 
ORc=1.3 ORc=1.6 ORc=1.9 ORc=4 ORc=6 
33/33 
(baseline) 
1.86 (1.33, 2.59) 1.86 (1.33, 2.59) 1.86 (1.33, 2.59) 1.86 (1.33, 2.59) 1.86 (1.33, 2.59) 
31/35 1.83 (1.31, 2.57) 1.82 (1.30, 2.54) 1.80 (1.29, 2.52) 1.75 (1.25, 2.44) 1.72 (1.23, 2.41) 
29/37 1.82 (1.30, 2.54) 1.78 (1.27, 2.49) 1.75 (1.25, 2.45) 1.64 (1.18, 2.30) 1.59 (1.14, 2.23) 
27/39 1.80 (1.28, 2.51) 1.75 (1.25, 2.44) 1.71 (1.22, 2.39) 1.55 (1.11, 2.16) 1.48 (1.06, 2.07) 
25/41 1.78 (1.27, 2.48) 1.71 (1.22, 2.39) 1.66 (1.19, 2.32) 1.46 (1.04, 2.04) 1.37 (0.98, 1.91) 
23/43 1.76 (1.26, 2.46) 1.68 (1.20, 2.35) 1.61 (1.15, 2.26) 1.37 (0.98, 1.91) 1.27 (0.91, 1.77) 
21/45 1.74 (1.24, 2.43) 1.64 (1.18, 2.30) 1.57 (1.12, 2.20) 1.29 (0.92, 1.80) 1.17 (0.84, 1.64) 
19/47 1.72 (1.23, 2.40) 1.61 (1.15, 2.25) 1.53 (1.09, 2.13) 1.21 (0.86, 1.69) 1.08 (0.77, 1.51) 
aModels are adjusted for SIMD, Charlson score, speciality for the index admission, any hospitalisation in the previous year (y/n), number of 484 
prescriptions in the previous year, number of different prescriptions in the previous year, days since the index admission until CDI, care 485 
home residence (y/n), PPI exposure (y/n) and H2 exposure (y/n) in the previous 6 months and unmeasured hospital prescribing. bP0: the 486 
prevalence of hospital antimicrobial prescribing in those who had not been given antimicrobials in the community; P1: the prevalence of 487 
hospital antimicrobial prescribing in those who have been prescribed antimicrobials in the community. cOR: assumed OR of hospital 488 
prescribing. 489 
Table A1: Sensitivity analysis - adjusted odds of HA-CDI associated with community prescribing of antimicrobials (Baseline) and assessment 490 
of the potential unmeasured confounder with different assumption of hospital antimicrobial prescribing rate (25%, 50%, 75%).  491 
 492 
Overall hospital 
prescribing rate 
hospital 
prescribing 
ratio: P0/P1b 
Difference 
between P0 
and P1 
Any antimicrobial 
Adjusteda OR of community prescribing (95% CI) 
ORc=1.3 ORc=1.6 ORc=1.9 ORc=4 ORc=6 
 baselined 0 1.41 (1.13, 1.75) 1.41 (1.13, 1.75) 1.41 (1.13, 1.75) 1.41 (1.13, 1.75) 1.41 (1.13, 1.75) 
33% 31/35 4 1.39 (1.12, 1.73) 1.38 (1.11, 1.71) 1.37 (1.10, 1.70) 1.32 (1.07, 1.64) 1.30 (1.05, 1.62) 
25% 23/27 4 1.39 (1.12, 1.73) 1.38 (1.11, 1.71) 1.37 (1.10, 1.70) 1.31 (1.06, 1.63) 1.29 (1.04, 1.60) 
50% 48/52 4 1.39 (1.12, 1.73) 1.38 (1.11, 1.71) 1.37 (1.11, 1.70) 1.34 (1.08, 1.66) 1.33 (1.07, 1.65) 
75% 73/77 4 1.39 (1.12, 1.73) 1.38 (1.11, 1.72) 1.38 (1.11, 1.71) 1.36 (1.09, 1.68) 1.35 (1.09, 1.67) 
33% 25/41 14 1.35 (1.08, 1.67) 1.30 (1.05, 1.61) 1.26 (1.01, 1.56) 1.10 (0.89, 1.37) 1.04 (0.84, 1.29) 
25% 17/33 14 1.35 (1.08, 1.67) 1.29 (1.04, 1.61) 1.25 (1.01, 1.55) 1.07 (0.86, 1.32) 0.98 (0.79, 1.22) 
50% 42/58 14 1.35 (1.09, 1.67) 1.31 (1.05, 1.62) 1.27 (1.03, 1.58) 1.16 (0.93, 1.44) 1.12 (0.90, 1.39) 
75% 67/83 14 1.35 (1.09, 1.68) 1.32 (1.06, 1.63) 1.29 (1.04, 1.60) 1.21 (0.98, 1.51) 1.19 (0.96, 1.47) 
33% 19/47 28 1.30 (1.05, 1.62) 1.22 (0.98, 1.52) 1.16 (0.93, 1.44) 0.92 (0.74, 1.14) 0.82 (0.66, 1.02) 
25% 11/39 28 1.30 (1.05, 1.61) 1.22 (0.98, 1.51) 1.14 (0.92, 1.42) 0.86 (0.69, 1.07) 0.74 (0.60, 0.92) 
50% 36/64 28 1.31 (1.05, 1.62) 1.24 (1.00, 1.53) 1.18 (0.95, 1.47) 1.00 (0.81, 1.24) 0.94 (0.76, 1.16) 
75% 61/89 28 1.31 (1.06, 1.63) 1.25 (1.01, 1.55) 1.21 (0.97, 1.50) 1.08 (0.87, 1.35) 1.05 (0.84, 1.30) 
Overall hospital 
prescribing rate 
hospital 
prescribing 
ratio: P0/P1b 
Difference 
between P0 
and P1 
4C antimicrobial 
Adjusteda OR of community prescribing (95% CI) 
ORc=1.3 ORc=1.6 ORc=1.9 ORc=4 ORc=6 
 baselined 0 1.86 (1.33, 2.59) 1.86 (1.33, 2.59) 1.86 (1.33, 2.59) 1.86 (1.33, 2.59) 1.86 (1.33, 2.59) 
33% 31/35 4 1.83 (1.31, 2.57) 1.82 (1.30, 2.54) 1.80 (1.29, 2.52) 1.75 (1.25, 2.44) 1.72 (1.23, 2.41) 
25% 23/27 4 1.83 (1.31, 2.57) 1.82 (1.30, 2.54) 1.80 (1.29, 2.52) 1.73 (1.24, 2.42) 1.70 (1.21, 2.37) 
50% 48/52 4 1.84 (1.31, 2.57) 1.82 (1.30, 2.55) 1.81 (1.29, 2.53) 1.77 (1.26, 2.47) 1.75 (1.25, 2.45) 
75% 73/77 4 1.84 (1.31, 2.57) 1.82 (1.30, 2.55) 1.82 (1.30, 2.54) 1.79 (1.28, 2.50) 1.78 (1.27, 2.49) 
33% 25/41 14 1.78 (1.27, 2.48) 1.71 (1.22, 2.39) 1.66 (1.19, 2.32) 1.46 (1.04, 2.04) 1.37 (0.98, 1.91) 
25% 17/33 14 1.77 (1.27, 2.48) 1.71 (1.22, 2.39) 1.65 (1.18, 2.31) 1.41 (1.01, 1.97) 1.30 (0.93, 1.81) 
50% 42/58 14 1.78 (1.27, 2.49) 1.72 (1.23, 2.41) 1.68 (1.20, 2.35) 1.53 (1.09, 2.14) 1.47 (1.05, 2.06) 
75% 67/83 14 1.78 (1.28, 2.49) 1.74 (1.24, 2.43) 1.70 (1.22, 2.38) 1.60 (1.14, 2.24) 1.57 (1.12, 2.19) 
33% 19/47 28 1.72 (1.23, 2.40) 1.61 (1.15, 2.25) 1.53 (1.09, 2.13) 1.21 (0.86, 1.69) 1.08 (0.77, 1.51) 
25% 11/39 28 1.72 (1.23, 2.40) 1.60 (1.15, 2.24) 1.51 (1.08, 2.11) 1.14 (0.81, 1.59) 0.97 (0.70, 1.36) 
50% 36/64 28 1.72 (1.23, 2.41) 1.63 (1.17, 2.28) 1.56 (1.11, 2.18) 1.32 (0.95, 1.85) 1.24 (0.88, 1.73) 
75% 61/89 28 1.73 (1.24, 2.42) 1.65 (1.18, 2.31) 1.60 (1.14, 2.23) 1.43 (1.02, 2.00) 1.38 (0.99, 1.93) 
aModels are adjusted for SIMD, Charlson score, speciality for the index admission, any hospitalisation in the previous year (y/n), number of prescriptions in the previous year, number of different prescriptions in the 493 
previous year, days since the index admission until CDI, care home residence (y/n), PPI exposure (y/n) and H2 exposure (y/n) in the previous 6 months and unmeasured hospital prescribing. bP0: the prevalence of 494 
hospital antimicrobial prescribing in those who had not been given antimicrobials in the community; P1: the prevalence of hospital antimicrobial prescribing in those who have been prescribed antimicrobials in the 495 
community. cOR: assumed OR of hospital prescribing. dbaseline OR are the same for different overall hospital antimicrobial prescribing rate (33%, 25%, 50%, 75%) as long as P0=P1. 496 
 497 
 498 
